IP Library Granted Patent US 7,820,634
Granted Patent B2
US 7,820,634 · App. 11/799,724 · Granted Oct 26, 2010

Composition and method for production of transformed cells

Assignees: Purdue Research Foundation; The Regents of the University of Michigan; Clarian Health Partners, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,634
App. No.
11/799,724
Granted
Oct 26, 2010
Kind
B2
Abstract

A composition useful for the production of transformed eukaryotic cells is described. The composition comprises submucosal tissue and a nucleic acid sequence. The nucleic acid sequence is typically recombinant DNA including gene(s) encoding for one or more biofunctional proteins. The submucosal tissue component of the present composition comprises the tunica submucosa of vertebrate intestine delaminated from the tunica muscularis and at least the luminal portion of the tunica mucosa. Injection or implantation of the composition into a host induces the formation of transformed cells capable of expressing gene(s) encoded by the nucleic acid sequence.

Claims (15)

1. A method for delivery of a deoxyribonucleic acid to cells of a host vertebrate species, said method comprising the step of contacting the cells in vivo with a composition comprising a collagenous matrix and an added exogenous deoxyribonucleic acid, wherein the collagenous matrix comprises submucosa tissue delaminated from both the tunica muscularis and at least the luminal portion of the tunica mucosa of warm-blooded vertebrate submucosa and wherein the deoxyribonucleic acid encodes a biofunctional protein.

2. The method of claim 1 , wherein the step of contacting the cells comprises the step of implanting the composition into the host vertebrate species.

3. The method of claim 1 , wherein the submucosa tissue is intestinal submucosa.

4. The method of claim 1 , wherein the submucosa tissue is in an injectable form and the step of contacting the cells comprises the step of injecting the composition into the host vertebrate species.

5. The method of claim 1 , wherein the collagenous matrix consists essentially of the tunica submucosa, and the basilar portion of the tunica mucosa of the intestine of a warm-blooded vertebrate.

6. The method of claim 1 , wherein the collagenous matrix comprises a component selected from the group consisting of a collagen, a glycoprotein, a proteoglycan, and a glycosaminoglycan.

7. The method of claim 1 , wherein the collagenous matrix is obtained from a source selected from the group consisting of porcine, bovine, and ovine species.

8. The method of claim 5 wherein the basilar portion of the tunica mucosa comprises the lamina muscularis mucosa and the stratum compactum.

9. The method of claim 1 wherein the collagenous matrix is obtained from a pig.

10. The method of claim 1 wherein the collagenous matrix is derived from intestinal tissue.

11. The method of claim 9 wherein the collagenous matrix is derived from intestinal tissue.

12. The method of claim 1 wherein the deoxyribonucleic acid comprises a plasmid.

13. The method of claim 1 wherein the deoxyribonucleic acid is a recombinant deoxyribonucleic acid.

14. The method of claim 1 wherein the submucosa tissue is in the form of a sheet.

15. The method of claim 1 wherein the submucosa tissue is in the form of strips.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 8, 2016
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038907/0765 →
Continuity (3)
Continuation 1071996500 · Nov 24, 2003
Continuation 0839070000 · Feb 17, 1995
Related Publication 20070202599A1 · Aug 30, 2007